Lonza promotes Stefan Troger to Visp site manager

Company: Lonza

He succeeds Stéphane Mischler, who retires next year

Lonza has promoted Stefan Troger to site manager of its plant in Visp, Switzerland. He takes up the role next April and will report to Harry Boot. With this appointment, leadership of the site and the Visp Challenge project will be merged into one.

Troger will succeed Stéphane Mischler, who after a long and impressive career spanning more than 30 years, is retiring. He will support Troger and the site management team until his retirement date and will also continue to work with Lonza’s pension fund.

Troger has held several positions within Lonza over the past 19 years. Most recently he was head of Biopharma Manufacturing in Visp and took over the leadership of the Visp Challenge project, which maps out the future set-up of the Visp site.

‘With Stefan Troger we have the possibility to unify the site leadership of the Visp site and project management of Visp Challenge,’ commented Stefan Borgas, chief executive of Lonza.

‘Our Visp site is confronted with major challenges in regards to currency, markets and technologies. The Visp Challenge project is working on two ends: increase productivity (lower cost and higher output from existing plants) in the short- and mid-term and improve the product portfolio to secure the future of Visp in the long-term.

‘Stefan Troger and his team have the right skill sets and the necessary level of positive energy to make this happen.’

You may also like

Manufacturing

Lonza expands bioconjugation capabilities for ADC manufacturing at Visp site

The CDMO's facility will double its bioconjugate manufacturing capacity with two 1,200 L manufacturing suites
Manufacturing

Lonza's Synaffix and BigHat Biosciences team up to develop ADC pipeline programme

Synaffix's clinical-stage ADC platform technology will allow BigHat to expand and progress its ADC pipeline for oncological indications
Manufacturing

Lonza extends its ADC manufacturing collaboration with biopharma giant through bioconjugation services

The CDMO will be responsible for the bioconjugation of the client's new solid tumour-targeting ADC, which will occur at its Visp site once it's extended
Finance

Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche

Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
Research & Development

AI-enabled route scouting: a faster and better way to successful synthesis

Despite the growing focus on biologics research, small molecules still make up the lion’s share of the medicines taken by patients every year
Manufacturing

Lonza to manufacture Vertex's CRISPR/Cas9 cell therapy, Casgevy

The one-time treatment will benefit patients with transfusion-dependent beta-thalassemia or sickle cell disease
Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Subscribe now